Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. - Wikidata - wikimedia - TriplyDB

Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

http://www.wikidata.org/entity/Q39945610

about

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress.Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer PSA regulates androgen receptor expression in prostate cancer cells.Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity.Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation Prostate cancer research in China.Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk Diet synergistically affects helicobacter pylori-induced gastric carcinogenesis in nonhuman primates.Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation.Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts Complementary and alternative medicine (CAM) in prostate and bladder cancer.Targeting kallikrein-related peptidases in prostate cancer.Androgen receptor coactivators that inhibit prostate cancer growth Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells.KLK-targeted Therapies for Prostate Cancer.Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity.Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.Neoadjuvant Enzalutamide Prior to Prostatectomy.The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male.Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen.Peptides binding to prostate-specific antigen enhance its antiangiogenic activity

P2860

Q33750087-D2B38894-8640-4392-9B2A-C4ADA952D77E Q33827212-76F25CB2-3077-4106-965E-395DB32DF33F Q33977438-CC71CA5C-E36F-4E00-A792-4AA4642EA7B6 Q35048230-36E0AEFA-5E25-4523-9372-412825E95336 Q35106686-6CEA76DA-52B9-4DD0-903C-627A1B557542 Q35176048-85E76F14-4B48-4B6B-8ED7-FE67E6ABDC30 Q36114365-4E2B44D1-3680-4718-BF0C-6C5443AB2EAA Q36382025-A081FF3C-F8E8-4D50-87DC-E2B22A417688 Q36496051-24C32783-A773-48A7-BEE8-6D91A20C3E79 Q36587631-A591E206-4894-4978-B972-F03B643C1B4E Q37034046-A4CF3148-C569-4E69-A834-C6321D300202 Q37085423-A2848FEA-900A-4FA1-8980-C2D1F338C370 Q37292847-D252D4B4-EBAF-4CE9-883B-1801346193FE Q37415394-AC7880E4-61FA-425C-9FE6-54A6E2E85990 Q37601718-97A2883E-CF85-4ECF-97C4-F78D9EFA8A9E Q37641177-FA412C12-4E34-4D6D-BE61-E508E1DAB10D Q38128885-3C8B4386-DEA4-44B6-833A-B047B1A02E79 Q38191293-0427B8F1-A03E-42BD-96FB-B38CAF785407 Q38265571-7E327FEB-D140-40DA-96E7-F913864303B9 Q38413737-16B736A8-07FB-498C-AF05-E23EDD1D1160 Q38737293-1EDD0A85-694D-4022-849C-1426351488F5 Q38760061-CBE5F605-2C4B-4B17-8344-E9F900036B74 Q38884397-DD4F1650-648B-4547-8503-F8D347A61101 Q38923071-65161B64-63ED-457C-9E2C-DB0B4C53820D Q38957297-44962739-4E57-4397-89DD-891C161E4031 Q38967486-4C329B8B-2AE5-4FCE-857D-A8733125A71B Q39079725-7516B823-ED8C-4899-B2CA-CAD0193EBA69 Q39470443-5C5E5158-44E5-4978-8DEF-DC0D91D57CFE Q39608321-C5E8DF59-2462-43F0-9D50-80848A2784D7 Q39769801-CBA5367B-7AA0-4BE5-8317-024B40D2098C Q46366990-4FBAC86D-8393-45F9-9A03-79B46F869B3F Q51488592-0DF7383F-A503-48E8-9A3A-AA94867DA020 Q51714928-5EC3FDC6-2F05-4665-8418-7635A77C14F4 Q56892046-084B2CF7-D8F0-433B-80FE-26DCEC04C99A

P2860

Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

http://www.wikidata.org/entity/Q39945610

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Tissue prostate-specific antig ...... ogen receptor transactivation.

@en

Tissue prostate-specific antig ...... ogen receptor transactivation.

@nl

type

label

Tissue prostate-specific antig ...... ogen receptor transactivation.

@en

Tissue prostate-specific antig ...... ogen receptor transactivation.

@nl

prefLabel

Tissue prostate-specific antig ...... ogen receptor transactivation.

@en

Tissue prostate-specific antig ...... ogen receptor transactivation.

@nl

P1433

Q39945610-D202EC9C-FCF5-4B0D-9757-FAF24671FE6F

P1476

Q39945610-1D489DF5-94CE-4AF4-A191-98BCAB258FE0

P2093

Q39945610-07FF13C0-7087-498D-B6F9-ECD45E0E3DA2

Q39945610-08FBDD42-8BED-4C80-A334-7318EF0FEECC

Q39945610-1DBF5DAD-24B3-45ED-97DB-A27BFC52FC11

Q39945610-239D1C45-DDB2-42CC-8E27-A9352A73D3B7

Q39945610-796841E8-4627-46AE-AB21-9A0F2CA7EA19

Q39945610-8516524E-A545-4EE4-9659-5DAC4FA50414

Q39945610-A13DC36D-7207-438D-8D8A-758D8615D21D

Q39945610-B290ECD4-24ED-484D-BFD3-0778B8AB414E

Q39945610-E04072DF-52AA-4FA2-A4FE-05F19963BA80

P2860

Q39945610-09C73F47-002F-4976-BF45-C496DAF74976

Q39945610-0FE0EA11-6985-4436-922B-76F57D2C18E5

Q39945610-1445C6B6-48C9-4274-A668-727E4C0395A0

Q39945610-1A622FCD-60BB-41A4-AA7E-2C6C81D01884

Q39945610-1DABC53C-61BB-4F6E-83CD-3734022EA9F8

Q39945610-1DDD53D2-C523-47D2-877D-A3EB7BD40EB3

Q39945610-298449F8-7E57-4034-954C-FBB7292801C6

Q39945610-2AD521AD-E0F9-4430-A6B8-96D6CB005FAF

Q39945610-2BDCD4DD-586E-460F-BBE6-325848877D98

Q39945610-354E9AEB-4F0E-44F0-A77B-4B589BAFEA66

P304

Q39945610-268875DD-7C11-4D26-B64B-4B0D0A9274AD

P31

Q39945610-72369477-1F07-4187-A7A2-3BD84AC13124

P356

Q39945610-C64E031D-2D24-433C-AF34-EFC336394325

P407

Q39945610-2CC11FDC-DE3A-44C3-8AEA-60B9A6282B8D

P433

Q39945610-77A04A64-9891-47BB-B24D-72BB9754F246

P478

Q39945610-9A231F38-9A7D-4E24-9092-0D7C103EBC95

P50

Q39945610-C72964D4-E4D0-4CA4-BD8E-68B5AF36B48D

P577

Q39945610-794BD6DE-A333-46CA-92A1-654E0DF637EE

P698

Q39945610-E32BBC31-EA7A-4768-830D-FAB76682AA77

P932

Q39945610-6AC4B9C1-3574-49C0-882F-15E3F503F709

P356

0008-5472.CAN-07-6507

P1433

Cancer Research

P1476

Tissue prostate-specific antig ...... ogen receptor transactivation.

@en

P2093

Chawnshang Chang

http://www.w3.org/2001/XMLSchema#string

Gonghui Li

http://www.w3.org/2001/XMLSchema#string

Hann-Chorng Kuo

http://www.w3.org/2001/XMLSchema#string

Jianqun Yuan

http://www.w3.org/2001/XMLSchema#string

Ruifa Han

http://www.w3.org/2001/XMLSchema#string

Saleh Altuwaijri

http://www.w3.org/2001/XMLSchema#string

Shuyuan Yeh

http://www.w3.org/2001/XMLSchema#string

Tengxiang Ma

http://www.w3.org/2001/XMLSchema#string

Yuanjie Niu

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells

Isolation and androgen regulation of the human homeobox cDNA, NKX3.1

A novel protease homolog differentially expressed in breast and ovarian cancer

Identification of 23 complementation groups required for post-translational events in the yeast secretory pathway.

Order of events in the yeast secretory pathway.

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen

Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma

Molecular determinants of resistance to antiandrogen therapy

Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells

P304

7110-7119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-07-6507

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Hiroshi Miyamoto

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18757426

http://www.w3.org/2001/XMLSchema#string

P932

2587124

http://www.w3.org/2001/XMLSchema#string